Catalog No.
DHC15807
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Human
Isotype
Fusion - [IL6ST (interleukin 6 signal transducer,
Target
Hybridoma growth factor, BSF-2, IFN-beta-2, CDF, IL6, Interleukin-6, IL-6, B-cell stimulatory factor 2, Interferon beta-2, IFNB2, CTL differentiation factor, sIL6R, Interleukin-6 receptor subunit alpha, CD126, IL-6R 1, IL-6R subunit alpha, Membrane glycoprotein 80, gp80, IL6R, IL-6RA, IL-6 receptor subunit alpha, IL-6R-alpha
Concentration
1.3 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P05231 & P08887
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
FE 999301,FE-301,FE-999301,gp130-Fc, CAS: 1702282-14-1
Clone ID
Olamkicept
Assessment of IL-6 Pathway Inhibition in Gastrointestinal Behçet's Disease from Immunological and Clinical Perspectives., PMID:39857830
A maternal high-fat diet predisposes to infant lung disease via increased neutrophil-mediated IL-6 trans-signaling., PMID:39535919
Obesity Arrhythmias: Role of IL-6 Trans-Signaling., PMID:39125976
Longitudinal single-cell data informs deterministic modelling of inflammatory bowel disease., PMID:38914538
Safety, tolerability, and pharmacokinetics of single- and multiple-ascending doses of olamkicept: Results from randomized, placebo-controlled, first-in-human phase I trials., PMID:38769747
Targeting IL-6 trans-signalling by sgp130Fc attenuates severity in SARS-CoV-2 -infected mice and reduces endotheliopathy., PMID:38677182
Nonspecific Inhibition of IL6 Family Cytokine Signalling by Soluble gp130., PMID:38338642
Differential Roles of Interleukin-6 in Severe Acute Respiratory Syndrome-Coronavirus-2 Infection and Cardiometabolic Diseases., PMID:38152628
An epithelial gene signature of trans-IL-6 signaling defines a subgroup of type 2-low asthma., PMID:38062491
Dissecting Interleukin-6 Classic and Trans-signaling in Inflammation and Cancer., PMID:37355548
Targeting IL-6 trans-signalling: past, present and future prospects., PMID:37069261
Crosstalk between microbiome, regulatory T cells and HCA2 orchestrates the inflammatory response in a murine psoriasis model., PMID:36891315
Effect of Induction Therapy With Olamkicept vs Placebo on Clinical Response in Patients With Active Ulcerative Colitis: A Randomized Clinical Trial., PMID:36881032
The Alzheimer's disease-linked protease BACE1 modulates neuronal IL-6 signaling through shedding of the receptor gp130., PMID:36810097
Defining the role of Interleukin-6 for the development of perioperative neurocognitive disorders: Evidence from clinical and preclinical studies., PMID:36778590
Corrigendum to "Olamkicept(sgp130Fc): The missing trial in Neuromyelitis Optica Spectrum Disorder" [Clinical Immunology 241 (2022) 109072]., PMID:36150949
Satralizumab might not be enough. Olamkicept (sgp130Fc) in Neuromyelitis Optica Spectrum Disorder., PMID:35835028
Olamkicept(sgp130Fc): The missing trial in Neuromyelitis Optica Spectrum Disorder., PMID:35798242
Case Report: Arterial Wall Inflammation in Atherosclerotic Cardiovascular Disease is Reduced by Olamkicept (sgp130Fc)., PMID:35754497
Exclusive inhibition of IL-6 trans-signaling by soluble gp130FlyRFc., PMID:34927050
A single aromatic residue in sgp130Fc/olamkicept allows the discrimination between interleukin-6 and interleukin-11 trans-signaling., PMID:34765926
Function and proteolytic generation of the soluble interleukin-6 receptor in health and disease., PMID:34626681
Interleukin-6: obstacles to targeting a complex cytokine in critical illness., PMID:33872590
Therapeutic Interleukin-6 Trans-signaling Inhibition by Olamkicept (sgp130Fc) in Patients With Active Inflammatory Bowel Disease., PMID:33667488
The role of interleukin-6 trans-signalling on cardiovascular dysfunction in inflammatory arthritis., PMID:33313793
Interleukin-6 signalling in health and disease., PMID:32864098
IL-6 Trans-Signaling in the Brain Influences the Metabolic Phenotype of the 3xTg-AD Mouse Model of Alzheimer's Disease., PMID:32630818
Soluble interleukin-6 receptor in patients with JAK2V617F somatic mutation and myeloproliferative neoplasm., PMID:32395711
Necroptosis, ADAM proteases and intestinal (dys)function., PMID:32381179
Development and Validation of a Reporter-Cell-Line-Based Bioassay for Therapeutic Soluble gp130-Fc., PMID:31731431
ADAM17 Activity and IL-6 Trans-Signaling in Inflammation and Cancer., PMID:31694340
Pharmacologic IL-6Rα inhibition in cholangiocarcinoma promotes cancer cell growth and survival., PMID:30419338
Inhibition of interleukin-6 trans-signaling prevents inflammation and endothelial barrier disruption in retinal endothelial cells., PMID:30240585
Evaluation of interleukin-6 and its soluble receptor components sIL-6R and sgp130 as markers of inflammation in inflammatory bowel diseases., PMID:29748708
Pharmacological inhibition of IL-6 trans-signaling improves compromised fracture healing after severe trauma., PMID:29497762
The Soluble Interleukin 6 Receptor: Advanced Therapeutic Options in Inflammation., PMID:28675418
Interleukin 6 trans-signaling regulates basal synaptic transmission and sensitivity to pentylenetetrazole-induced seizures in mice., PMID:28481031
Proteolytic Cleavage Governs Interleukin-11 Trans-signaling., PMID:26876177
Peripheral and central blockade of interleukin-6 trans-signaling differentially affects sleep architecture., PMID:26144889
IL-6 trans-signaling plays important protective roles in acute liver injury induced by acetaminophen in mice., PMID:25914167
Inhibition of IL-6 signaling significantly reduces primary tumor growth and recurrencies in orthotopic xenograft models of pancreatic cancer., PMID:25604508
Interleukin-6: from basic biology to selective blockade of pro-inflammatory activities., PMID:24325804
Interleukin-6 trans-signaling exacerbates inflammation and renal pathology in lupus-prone mice., PMID:23818297
Interleukin-6 trans-signaling and colonic cancer associated with inflammatory bowel disease., PMID:23108305
Recombinant IL-6 treatment protects mice from organ specific autoimmune disease by IL-6 classical signalling-dependent IL-1ra induction., PMID:22980031
Therapeutic targeting of interleukin-6 trans-signaling does not affect the outcome of experimental tuberculosis., PMID:22387074
Transsignaling of interleukin-6 crucially contributes to atherosclerosis in mice., PMID:22075248
Blockade of interleukin-6 in murine sepsis revisited: is there an indication for a new therapy in human patients?, PMID:21610636
Selective blockade of interleukin-6 trans-signaling improves survival in a murine polymicrobial sepsis model., PMID:21336117
IL-6 trans-signaling in formation and progression of malignant ascites in ovarian cancer., PMID:21123455
For research use only. Not for human or drug use.
